

Abstract session: Alternatives to standard aortic prostheses

Moderated by M. Moon, St Louis | Thursday 8th October | 14:45–16:15 | Room 111–112

Abstract
session

This session provides an overview of various alternatives to standard aortic prostheses for the treatment of patients with aortic valve disease. Clinical and/or real-world outcomes are presented for bioprostheses, mechanical, rapid deployment, sutureless and decellularised valves.

Presentations

- | | |
|-------|---|
| 15:00 | Clinical outcomes of the Perceval and Perceval Plus aortic bioprostheses from a real-world registry M Scherner <i>et al.</i> |
| 15:09 | Sutureless <i>versus</i> rapid deployment aortic valve replacement: Results from the Sutureless and Rapid Deployment International Registry P Berretta <i>et al.</i> |
| 15:18 | Propensity matched long-term analysis of mechanical <i>versus</i> stentless aortic valve replacement in the younger patient T Christ <i>et al.</i> |
| 15:27 | Long-term outcomes in patients with low flow low gradient after Ozaki procedure V Bazylev <i>et al.</i> |
| 15:36 | First-in-human study with a 3-D shaped, single piece, decellularized aortic valve B Meuris <i>et al.</i> |
| 15:45 | Bental procedure after previous aortic valve or complete root replacement: Usefulness of self-assembled valve conduit V Irimie <i>et al.</i> |
| 15:55 | Clinical performance of 210 INSPIRIS bioprostheses D Geisler <i>et al.</i> |
| 16:04 | Aortic and pulmonary valve replacement with decellularized homografts A Andreeva <i>et al.</i> |
| 16:13 | Permanent pacemaker implantation following sutureless/rapid deployment aortic valve replacement: A progress report from an international registry F Pollari <i>et al.</i> |

Key takeaways

- A large multicentric analysis comparing sutureless and rapid deployment (SURD) valves showed good efficacy and safety of the sutureless PERCEVAL valve and the rapid deployment INTUITY valve in isolated and combined procedures
 - The PERCEVAL valve demonstrated reduced operative times and shorter hospital stays
 - The INTUITY valve demonstrated superior haemodynamic outcomes and a lower incidence of postoperative mild aortic regurgitation
- This study compares long-term outcomes with stentless and mechanical valves for aortic valve replacement
- There were no differences in hospital outcome, long-term stroke- and bleeding-rate, and survival with the two valve types
- Freedom from reoperation was significantly higher with mechanical *versus* stentless valves
- Stentless valves are not ideal for younger patients due to complicated re-operation; stented biological aortic valve replacement is preferable
- The new generation INSPIRIS RESILIA bioprosthetic valve uses novel preservation technology of bovine pericardial tissue to improve haemodynamic performance and durability
- In this retrospective, single centre study, the INSPIRIS RESILIA valve demonstrated good haemodynamic performance at discharge and more than 1-year follow-up, with no cases of early structural valve deterioration.

[Click here for more information on the EACTS 2020 scientific programme.](#)

You might also be interested in...

RESILIENCE trial study design: evaluating the durability of RESILIA tissue valves in subjects under 65 years old

Keywords: aortic bioprostheses, aortic valve replacement, structural valve degeneration [...]

March 26, 2020

Excellent 2-year outcomes for new bioprosthetic tissue

Keywords: COMMENCE trial, INSPIRIS RESILIA, bioprosthetic tissue, paravalvular leak [...]

July 12, 2017

Important safety information:

Use of the EDWARDS INTUITY Elite valve system may be associated with new or worsened conduction disturbances, which may require a permanent cardiac pacemaker implant (PPI). The rate of PPI for the EDWARDS INTUITY Elite valve is within the range reported in the literature for various rapid deployment valves, but higher than that reported for surgical aortic valves. Physicians should assess the benefits and risks of the EDWARDS INTUITY Elite valve prior to implantation. See instructions for use for additional information. For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards INTUITY, Edwards INTUITY Elite and INSPIRIS RESILIA are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. NP--EU-0142 V.10

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards